1
|
66P DDB2 influences epithelial-to-mesenchymal transition and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma cells. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
47P Comprehensive molecular analysis of tissue samples from cancer patients: Evaluation of a novel all-in-one NGS strategy for diagnosis and theranostics. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Exploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
First national external quality assessment for the interpretation of somatic variants: Assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Two years of BRCA1 and BRCA2 somatic external quality assessment with Gen&Tiss scheme in France. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Mutations du gène ESR1 : du fondamental à la clinique. ONCOLOGIE 2019. [DOI: 10.3166/onco-2019-0027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
L’hormonorésistance acquise constitue l’un des défis majeurs dans le traitement du cancer du sein avancé exprimant le récepteur aux estrogènes (RE) et sans surexpression de HER2. Les mutations activatrices du gène ESR1 affectant le domaine de liaison du ligand ont récemment été identifiées comme l’un des principaux mécanismes de résistance aux inhibiteurs de l’aromatase (IA). Ces mutations peuvent être recherchées sur des prélèvements histologiques ou sur ADN tumoral circulant, par PCR ou séquençage de nouvelle génération (NGS). Elles induisent une activation constitutionnelle du RE conduisant à une résistance acquise aux IA ; le tamoxifène, le fulvestrant et les thérapies ciblées anti-mTOR ou anti-CDK4/6 conservent leur efficacité. La place en pratique clinique de la détection des mutations du gène ESR1 reste encore à définir.
Collapse
|
7
|
Detection of ALK, RET, ROS1, NTRK1 and MET rearrangements and actionable mutations using next generation sequencing in patients with non-small cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy318.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Abstract P2-01-30: Limited effectiveness of patent blue dye in addition to isotope scanning for identification of sentinel lymph nodes: Cross-sectional real-life study in 1024 breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
|